Quotient Ltd. (QTNT) Lowered to Sell at Zacks Investment Research
Quotient Ltd. (NASDAQ:QTNT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “
Quotient (NASDAQ:QTNT) opened at 7.595 on Wednesday. The stock’s market capitalization is $109.19 million. The company’s 50-day moving average price is $7.32 and its 200 day moving average price is $8.27. Quotient has a 52 week low of $5.67 and a 52 week high of $17.44.
In other Quotient news, Director L John Wilkerson acquired 180,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were purchased at an average cost of $5.50 per share, for a total transaction of $990,000.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider D J. Paul E. Cowan acquired 45,455 shares of the firm’s stock in a transaction that occurred on Wednesday, August 3rd. The stock was acquired at an average price of $5.50 per share, for a total transaction of $250,002.50. Following the completion of the acquisition, the insider now directly owns 26,666 shares of the company’s stock, valued at approximately $146,663. The disclosure for this purchase can be found here. 40.50% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC acquired a new position in Quotient during the first quarter worth approximately $105,000. First New York Securities LLC NY acquired a new position in Quotient during the second quarter worth approximately $140,000. Schonfeld Strategic Advisors LLC purchased a new position in Quotient during the first quarter worth approximately $172,000. BlackRock Investment Management LLC boosted its position in Quotient by 2.5% in the second quarter. BlackRock Investment Management LLC now owns 86,418 shares of the company’s stock worth $670,000 after buying an additional 2,075 shares during the period. Finally, Bellevue Group AG purchased a new position in Quotient during the first quarter worth approximately $880,000. Hedge funds and other institutional investors own 41.50% of the company’s stock.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quotient Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.